// App-Quantinova.ai

43 : Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study.

Researchers

Presenter

  • Dana E. Rathkopf

Principal Investigators

  • Daniel Costin Danila

  • Michael J. Morris

  • Steven M. Larson

  • Howard I. Scher

  • Susan F. Slovin

  • Jill Elise Steinbrecher

  • Gabrielle Arauz

  • Peter J. Rix

  • Edna Chow Maneval

  • Isan Chen

  • Josef J. Fox

  • Martin Fleisher

Medical Centers

  • Seragon Pharmaceuticals, San Diego, CA

  • Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY

  • Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

Drug/Treatment

  • ARN-509

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved